Name the lane
Decision points
The most useful comparison is not clinic against clinic. It is approved medicine against compounded medicine against a chemical sold for research.
Do not compare unlike things.
Side by side
Approved
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) were each on the FDA’s approved list in some version by September 2026.
As of September 2026, FDA approval covers one exact medicine in one exact form, for example an injection or a tablet. It also covers only the uses listed in the FDA’s records. On that date, putting a famous brand name on a different mixture did not make it the approved medicine.
Compounded
As of September 2026, a licensed pharmacist or doctor can mix medicine for one patient’s need instead of handing over a factory-made product.
Compounded drugs, as of September 2026, hold no FDA approval, and the agency never looks over each one for safety, effectiveness or quality before a patient gets it.
Research-only
A chemical offered online with a research label is not a prescription pathway.
In its warning letters, as of September 2026, the FDA treats a product sold for human use as an unapproved drug, even if the label says research only. That label does not make it a lawful treatment.
Marketing language
As of September 2026, federal rules say that listing a facility or drug does not grant approval and does not prove the product can legally be marketed.
An NDC number is a product code on a federal drug list. That difference matters when a website points to an NDC number, a badge claiming a government listing, or the words “FDA registered.” Ask for the actual product name and the pharmacy name instead.